

# Risk Evaluation and Mitigation Strategy (REMS) Document

## NATPARA (parathyroid hormone) REMS Program

### I. Administrative Information

Application Number: BLA 125511

Application Holder: Shire-NPS Pharmaceuticals, Inc

Initial REMS Approval: 01/2015

Most Recent REMS Update: 06/2020

### II. REMS Goal

The goal of the NATPARA REMS Program is to mitigate the potential risk of osteosarcoma associated with NATPARA by:

1. Ensuring that prescribers are educated on the following:
  - potential risk of osteosarcoma associated with the use of NATPARA
  - appropriate patient selection
  - safe-use conditions required for prescribing NATPARA
2. Ensuring that NATPARA is dispensed only to patients informed about the potential risk of osteosarcoma associated with the use of NATPARA

### III. REMS Requirements

Shire-NPS Pharmaceuticals, Inc must ensure that healthcare providers, patients, pharmacies, and wholesalers-distributors comply with the following requirements:

---

#### 1. Healthcare providers who prescribe NATPARA must:

- |  |   |
|--|---|
| To become certified to prescribe         | <ol style="list-style-type: none"><li>1. Review the drug's Prescribing Information.</li><li>2. Review the <a href="#">REMS Program: An Introduction</a>.</li><li>3. Review the following: <a href="#">Training Module for Prescribers</a>.</li><li>4. Successfully complete the <a href="#">Knowledge Assessment</a> and submit it to the REMS Program.</li><li>5. Enroll in the REMS by completing the <a href="#">Prescriber Enrollment Form</a> and submitting it to the REMS Program.</li></ol> |
| Before treatment initiation (first dose) | <ol style="list-style-type: none"><li>6. Counsel the patient on the appropriate use and risks associated with NATPARA using the <a href="#">Patient Brochure</a>. Provide a copy of the material to the patient.</li><li>7. Enroll the patient by completing and submitting the <a href="#">Patient-Prescriber Acknowledgment Form</a> to the REMS Program. Retain a completed copy in the patient's record.</li></ol>  |

---

#### 2. Patients who are prescribed NATPARA:

- |                             |   |
|-----------------------------|---|
| Before treatment initiation | <ol style="list-style-type: none"><li>1. Receive counseling from the prescriber on the appropriate use and risks associated with NATPARA using the <a href="#">Patient Brochure</a>.</li><li>2. Enroll in the REMS Program by completing the <a href="#">Patient-Prescriber Acknowledgment Form</a> with the prescriber. Enrollment information will be</li></ol> |
|-----------------------------|---|

---

provided to the REMS Program.

### 3. Pharmacies that dispense NATPARA must:

---

To become certified to dispense	<ol style="list-style-type: none"><li>1. Designate an authorized representative to carry out the certification process on behalf of the pharmacy and oversee implementation and compliance with the REMS Program on behalf of the pharmacy.</li><li>2. Have the authorized representative review the Prescribing Information, <a href="#">REMS Program: An Introduction</a>, and <a href="#">Training Module for Pharmacy Representatives</a>.</li><li>3. Have the authorized representative successfully complete the <a href="#">Knowledge Assessment</a> and submit it to the REMS Program.</li><li>4. Have the authorized representative enroll in the REMS Program by completing the <a href="#">Pharmacy Enrollment Form</a> and submitting it to the REMS Program.</li><li>5. Train all relevant staff involved in dispensing NATPARA on the REMS program requirements using the <a href="#">Training Module for Pharmacy Representatives</a>.</li><li>6. Establish processes and procedures to verify the prescriber is certified and the patient is enrolled in the REMS Program.</li></ol>
Before dispensing	<ol style="list-style-type: none"><li>7. Verify that the prescriber is certified, and the patient is enrolled in the REMS through the processes and procedures established as a requirement of the REMS Program.</li></ol>
To maintain certification to dispense	<ol style="list-style-type: none"><li>8. Have any new authorized representative review the Prescribing Information, <a href="#">REMS Program: An Introduction</a>, and <a href="#">Training Module for Pharmacy Representatives</a>.</li><li>9. Have any new authorized representative successfully complete the <a href="#">Knowledge Assessment</a> and submit it to the REMS Program.</li><li>10. Have any new authorized representative enroll in the REMS Program by completing the <a href="#">Pharmacy Enrollment Form</a> and submitting it to the REMS Program.</li></ol>
At all times	<ol style="list-style-type: none"><li>11. Not distribute, transfer, loan, or sell NATPARA.</li><li>12. Maintain records of staff's completion of training.</li><li>13. Maintain records that all REMS processes and procedures are in place and are being followed.</li><li>14. Maintain and submit records of all prescription data to the REMS Program.</li><li>15. Comply with audits carried out by Shire-NPS Pharmaceuticals, Inc or a third party acting on behalf of Shire-NPS Pharmaceuticals, Inc to ensure that all processes and procedures are in place and are being followed.</li></ol>

---

### 4. Wholesalers-Distributers that distribute NATPARA must:

---

To be able to distribute	<ol style="list-style-type: none"><li>1. Establish processes and procedures to ensure that the drug is distributed only to certified pharmacies.</li></ol>
--------------------------	--

---

---

	2. Train all relevant staff involved in distributing NATPARA on the REMS requirements.
At all times	3. Distribute only to certified pharmacies.  4. Maintain and submit records of all shipments and distribution data.  5. Comply with audits carried out by Shire-NPS Pharmaceuticals, Inc or a third party acting on behalf of Shire-NPS Pharmaceuticals, Inc to ensure that all processes and procedures are in place and are being followed.

---

**Shire-NPS Pharmaceuticals, Inc. must provide training to healthcare providers who prescribe NATPARA.** The training includes the following educational materials: [REMS Program: An Introduction](#), [Training Module for Prescribers](#), and [Knowledge Assessment](#). The training must be available online and by calling the Coordinating Center.

**Shire-NPS Pharmaceuticals, Inc. must provide training to pharmacies that dispense NATPARA.** The training includes the following educational materials: [REMS Program: An Introduction](#), [Training Module for Pharmacy Representatives](#), and [Knowledge Assessment](#). The training must be online and by calling the Coordinating Center.

**To support REMS Program operations, Shire-NPS Pharmaceuticals, Inc. must:**

1. Establish and maintain a REMS Program website, [www.NATPARAREMS.com](http://www.NATPARAREMS.com). The REMS Program website must include the capability to complete prescriber certification and enrollment online and the option to print the Prescribing Information, Medication Guide and REMS materials. All product websites for consumers and healthcare providers must include prominent REMS-specific links to the REMS Program website. The REMS Program website must not link back to the promotional product website(s).
2. Make the REMS Program website fully operational and all REMS materials available through the website and coordinating center within 60 calendar days of the REMS modification.
3. Establish and maintain a REMS Program coordinating center for REMS participants at (1-855-NATPARA (628-7272)).
4. Establish and maintain a validated, secure database of all REMS participants who are enrolled and/or certified in the NATPARA REMS Program.
5. Ensure prescribers are able to enroll in the REMS by fax, email, and online.
6. Ensure pharmacies are able to enroll in the REMS by fax and email.
7. Ensure prescribers are able to enroll patients by fax and email.
8. Ensure pharmacies are able to verify prescriber certification and patient enrollment online.
9. Provide the [REMS Program: An Introduction](#), [Training Module for Prescribers](#), [Prescriber Enrollment Form](#), [Patient Brochure](#), [Patient-Prescriber Acknowledgment Form](#), and the Prescribing Information to healthcare providers who (1) attempt to prescribe NATPARA and are not yet certified, or (2) inquire about how to become certified.

10. Provide the [REMS Program: An Introduction, Training Module for Pharmacy Representatives, Pharmacy Enrollment Form](#), and the Prescribing Information to pharmacies that inquire about how to become certified.
11. Notify healthcare providers and pharmacies after they become certified in the REMS Program.
12. Provide certified pharmacies access to the database of certified prescribers and enrolled patients.
13. Provide authorized wholesalers-distributors access to the database of certified pharmacies.

**To ensure REMS participants' compliance with the REMS Program, Shire-NPS Pharmaceuticals, Inc. must:**

14. Verify every 2 years that the authorized representative's name and contact information corresponds to that of the current designated authorized representative for the certified pharmacy. If different, the pharmacy must be required to re-certify with a new appointed authorized representative.
15. Maintain adequate records to demonstrate that REMS requirements have been met, including but not limited to records of: NATPARA distribution and dispensing, certification of prescribers, pharmacies; enrolled patients; and audits of REMS participants. These records must be readily available for FDA inspections.
16. Establish a plan for addressing non-compliance with REMS Program requirements.
17. Monitor prescribers, pharmacies, and wholesalers-distributors on an ongoing basis to ensure the requirements are being met. Take corrective action if non-compliance is identified, including decertification.
18. Audit certified pharmacies within 30 calendar days after the pharmacy is certified, to ensure that all processes and procedures are in place, functioning, and support the REMS Program requirements. Certified pharmacies must also be included in the annual audit plan.
19. Audit wholesalers-distributors within 180 calendar days after the first shipment of NATPARA, to ensure that all processes and procedures are in place, functioning, and support the REMS Program requirements.
20. Take reasonable steps to improve implementation of and compliance with the requirements in the NATPARA REMS Program based on monitoring and evaluation of the NATPARA REMS Program.

#### **IV. REMS Assessment Timetable**

Shire-NPS Pharmaceuticals, Inc must submit REMS Assessments every two years beginning with the REMS assessment for year six (72-month; January 22, 2020). To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment. Shire-NPS Pharmaceuticals, Inc must submit each assessment so that it will be received by the FDA on or before the due date.

#### **V. REMS Materials**

The following materials are part of the NATPARA REMS:

##### **Enrollment Forms**

Prescriber:

1. [Prescriber Enrollment Form](#)

Patient:

2. [Patient-Prescriber Acknowledgement Form](#)

Pharmacy:

3. [Pharmacy Enrollment Form](#)

### **Training and Educational Materials**

Prescriber:

4. [REMS Program: An Introduction](#)
5. [Training Module for Prescribers](#)
6. [Knowledge Assessment](#)

Patient:

7. [Patient Brochure](#)

Pharmacy:

8. [REMS Program: An Introduction](#)
9. [Training Module for Pharmacy Representatives](#)
10. [Knowledge Assessment](#)

### **Other Materials**

11. [REMS Program website](#)